



CLLPAG welcomes Rebecca Drotos to the Chair position. Rebecca has been an active CLLPAG Director since 2013.

There are currently 3 important surveys posted on the CLLPAG website
cllpag.ca [Surveys](#)

1. SURVEY FOR PATIENTS USING VENETOCLAX AND RITUXIMAB COMBINATION

Lymphoma Canada and the CLL Patient Advocacy Group (CLLPAG) are preparing a submission for the pan-Canadian Oncology Drug Review (pCODR) for: **Venetoclax (Venclexta) and rituximab (Rituxan), for the treatment of patients with relapsed/refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).** (based on Murano Trial data)

2. SURVEY ON CLINICAL TRIAL PARTICIPATION – GO CART RESEARCH TEAM

To better plan the Canadian CAR-T clinical trial, Ottawa Hospital wants to hear from people who are currently being treated, or have been treated, for blood cancer on their views about clinical trials for new therapies for blood cancer.

3. ALL.CAN INTERNATIONAL CANCER PATIENT SURVEY

Specifically focuses on waste and inefficiency in cancer care and treatment. The patient survey has just launched in Canada (in English and in French) and we are looking to reach as many cancer patients, and their families, as possible and with as broad a range of cancer types as possible.

Health Canada has issued a Notice of Compliance for **VENCLEXTA® (venetoclax)** in combination with rituximab for the treatment of adult patients with chronic lymphocytic leukemia (CLL) who have received at least one prior therapy. The next step is pCODR (pan-Canadian Oncology Drug Review) and CLLPAG and Lymphoma Canada are preparing a patient submission to pCODR.

Be sure to checkout the CLL Live 2018 [Videos](#)
